Nucleolin Promotes Cisplatin Resistance in Cervical Cancer by the YB1-MDR1 Pathway

Rucaparib antagonize multidrug resistance in cervical cancer cells through blocking the function of ABC transporters

(2020) Zhen Chen et al.   GENE

Oncogenic Y‐box binding protein‐1 ( YBX 1) as an effective therapeutic target in drug‐resistant cancer

(2019) Michihiko Kuwano et al.   CANCER SCIENCE

Nucleolin-based targeting strategies for cancer therapy: from targeted drug delivery to cytotoxic ligands

(2019) Sofia Romano et al.   DRUG DISCOVERY TODAY

New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment

(2019) Shang-Hung Chen et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Targeting Nucleolin for Reversal of Chemotherapy Resistance in Acute Lymphoblastic Leukemia

(2019) Jianda Hu et al.   BLOOD

Mechanisms of acquired tumor drug resistance

(2019) Svetlana N. Aleksakhina et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance

(2019) Tomohiro Shibata et al.   MOLECULAR CANCER THERAPEUTICS

Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis

(2019) Marc Arbyn et al.   Lancet Global Health

Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer

(2018) Eya Wolfson et al.   Cell Death & Disease

Targeting surface nucleolin induces autophagy-dependent cell death in pancreatic cancer via AMPK activation

(2018) Cheng Xu et al.   ONCOGENE

Aberrant expression of CITED2 promotes prostate cancer metastasis by activating the nucleolin-AKT pathway

(2018) Seung-Hyun Shin et al.   Nature Communications

New perspectives of physiological and pathological functions of nucleolin (NCL)

(2017) Wenyu Jia et al.   LIFE SCIENCES

Expression levels of resistant genes affect cervical cancer prognosis

(2017) Fengmei Yang et al.   Molecular Medicine Reports

Roles of nucleolin. Focus on cancer and anti-cancer therapy

(2016) Zhuo Chen et al.   SAUDI MEDICAL JOURNAL

Molecular mechanisms of cisplatin resistance in cervical cancer

(2016) Xueqiong Zhu et al.   Drug Design Development and Therapy

The roles of nucleolin subcellular localization in cancer

(2015) Caroline Madeleine Berger et al.   BIOCHIMIE

Cell Surface Nucleolin as a Target for Anti-Cancer Therapies

(2014) Marina Koutsioumpa et al.   Recent Patents on Anti-Cancer Drug Discovery

A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma

(2013) Jonathan E. Rosenberg et al.   INVESTIGATIONAL NEW DRUGS

Short hairpin RNA targeting Twist1 suppresses cell proliferation and improves chemosensitivity to cisplatin in HeLa human cervical cancer cells

(2012) KEXIU ZHU et al.   ONCOLOGY REPORTS

Molecular mechanisms of cisplatin resistance

(2011) L Galluzzi et al.   ONCOGENE

Nucleolin on the Cell Surface as a New Molecular Target for Gastric Cancer Treatment

(2010) Tatsuro Watanabe et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Mechanism of Regulation ofbcl-2mRNA by Nucleolin and A+U-rich Element-binding Factor 1 (AUF1)

(2010) Daniella Ishimaru et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Plasma Membrane Nucleolin Is a Receptor for the Anticancer Aptamer AS1411 in MV4-11 Leukemia Cells

(2009) S. Soundararajan et al.   MOLECULAR PHARMACOLOGY

Regulatory Role of Human AP-Endonuclease (APE1/Ref-1) in YB-1-Mediated Activation of the Multidrug Resistance Gene MDR1

(2008) R. Chattopadhyay et al.   MOLECULAR AND CELLULAR BIOLOGY